Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

109

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

109 results for “primary central nervous system lymphoma”

Learn how ShareScore rates datasets ↗
zenodo44/100

The genomic and transcriptional landscape of primary central nervous system lymphoma

<p>Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell lymphomas (DLBCLs) confined to the central nervous system (CNS). Despite extensive research, the molecular alterations leading to PCNSL have not been fully elucidated. In order to provide a comprehensive description of the genomic and transcriptional landscape of PCNSL, we here performed whole-genome and transcriptome sequencing and integrative analysis of 51 lymphomas presenting in the CNS, including 42 EBV-negative PCNSL, 6 secondary CNS lymphomas (SCNSL) and 3 EBV+ CNSL and matched controls. The results were compared to an independent validation cohort of 31 FFPE CNSL specimens (PCNSL, n = 19; SCNSL, n = 9; EBV+ CNSL, n = 3) and 36 systemic DLBCL cases outside the CNS.</p> <p>This repository contains tab&nbsp;separated value text files:</p> <p>-&nbsp;Radke_et_al_supplementary_somatic_CNVs.tsv (somatic copy number variations predicted by ACEseq)<br> - Radke_et_al_supplementary_somatic_indels.tsv (somatic indels predicted by the DKFZ platypus workflow)<br> - Radke_et_al_supplementary_somatic_indels_exonic.tsv&nbsp;(somatic exonic indels predicted by the DKFZ platypus workflow)<br> - Radke_et_al_supplementary_somatic_mutations_integrated.tsv (table of gene by patients, stating which mutations were observed)&nbsp; &nbsp;&nbsp;<br> - Radke_et_al_supplementary_somatic_mutations_integr_integrated_including_kataegis_counts.tsv&nbsp;&nbsp; (table of gene by patients, stating which mutations were observed, including the count of mutations falling into kataegis hotspots)&nbsp; &nbsp;&nbsp;<br> - Radke_et_al_supplementary_somatic_SNVs.tsv&nbsp;(somatic SNVs predicted by the DKFZ mpileup workflow)<br> - Radke_et_al_supplementary_somatic_SNVs_exonic_functional.tsv&nbsp;(somatic exonic SNVs predicted by the DKFZ mpileup workflow)<br> - Radke_et_al_supplementary_somatic_SNVs_rescued_by_TiNDA&nbsp;(mutations initially classified as germline, but likely tumor mutations based on VAF modelling by TiNDA)<br> - Radke_et_al_supplementary_somatic_SVs.tsv (somatic structural variations predicted by the DKFZ Sophia workflow)<br> - Radke_et_al_supplementary_RNAseq_numReads_CNSLs.tsv (RNAseq read counts calculated by the DKFZ RNAseq workflow)</p> <p>This repository contains the raw unedited images from the manuscript:</p> <p>- Radke_et_al_Main_Figure_1c_BCL6.tif &nbsp;(raw unedited image for Main Figure 1c - BCL6)<br> - Radke_et_al_Main_Figure_1c_CD10.tif &nbsp;(raw unedited image for Main Figure 1c - CD10)<br> - Radke_et_al_Main_Figure_1c_MUM1.tif &nbsp;(raw unedited image for Main Figure 1c - MUM1)<br> - Radke_et_al_Supplementary_Figure_1a_CD20.tif &nbsp;(raw unedited image for Supplementary Figure 1a - CD20)<br> - Radke_et_al_Supplementary_Figure_1a_EBV.tif &nbsp;(raw unedited image for Supplementary Figure 1a - EBV)<br> - Radke_et_al_Supplementary_Figure_1a_HE_(FFPE).tif &nbsp;(raw unedited image for Supplementary Figure 1a - HE (FFPE))<br> - Radke_et_al_Supplementary_Figure_1a_HE_(frozen)_1.tif &nbsp;(raw unedited image for Supplementary Figure 1a - HE (frozen) 1)<br> - Radke_et_al_Supplementary_Figure_1a_HE_(frozen)_2.tif &nbsp;(raw unedited image for Supplementary Figure 1a - HE (frozen) 2)<br> - Radke_et_al_Supplementary_Figure_1a_HE_(frozen)_3.tif &nbsp;(raw unedited image for Supplementary Figure 1a - HE (frozen) 3)<br> - Radke_et_al_Supplementary_Figure_1a_Ki67.tif &nbsp;(raw unedited image for Supplementary Figure 1a - Ki67)<br> - Radke_et_al_Supplementary_Figure_1b_EBV_PCR.pptx &nbsp;(raw unedited image for Supplementary Figure 1b - EBV PCR&nbsp;)<br> - Radke_et_al_Supplementary_Figure_1c_CDKN2A_FISH_1.jpg &nbsp;(raw unedited image for Supplementary Figure 1c - CDKN2A FISH 1)<br> - Radke_et_al_Supplementary_Figure_1c_CDKN2A_FISH_2.jpg &nbsp;(raw unedited image for Supplementary Figure 1c - CDKN2A FISH 2)<br> - Radke_et_al_Supplementary_Figure_7h_PD-L1_LS-033.tif &nbsp;(raw unedited image for Supplementary Figure 7h - PD-L1 LS-033)<br> - Radke_et_al_Supplementary_Figure_7h_PD-L1_LS-031.tif &nbsp;(raw unedited image for Supplemnetary Figure 7h - PD-L1 LS-031)</p>

opencc-by-4.0Jul 2021View details →
zenodo40/100

Processed Vectra images for primary central nervous system lymphoma (PCNSL) patients

<ul> <li>FFPE materials</li> </ul> <p>Formalin-fixed paraffin-embedded (FFPE) tumor samples and clinical data were obtained from PCNSL patients enrolled in the HOVON105/ALLG NHL 24 intergroup, multicenter, open-label, randomized phase 3 study (NTR2437 and ACTRN12610000908033)&nbsp;through the HOVON Pathology Facility and Biobank.&nbsp;</p> <ul> <li>Muiltiplex imaging</li> </ul> <p>Multiplex immunofluorescence was performed on 4-&micro;m-thick formalin-fixed, paraffin-embedded whole tissue sections using the Opal 7-color fluorescence immunohistochemistry (IHC) kit (Akoya biosciences, USA), as previously described. In brief, slides were deparaffinized and rehydrated, followed by a blocking step for endogenous peroxidase using 0.3% H<sub>2</sub>O<sub>2</sub>/methanol and fixation with 10% neutral buffered formalin (Leica Biosystems, Germany). Slides were washed in Milli-Q water and 0.05% Tween20 in 1x Tris-Buffered Saline (TBS-T). Antigen retrieval was done by placing the slides in 0.05% ProClin300/Tris&ndash;EDTA buffer pH 9.0 in a microwave at 100% power until boiling, followed by 15 min at 30% power. Slides were cooled in Milli-Q water, washed in 1x TBS-T and blocked with Antibody Diluent (Agilent, USA). The slides were then incubated with primary antibody diluted in Normal Antibody Diluent, followed by incubation with the broad spectrum HRP from the SuperPicture Polymer Detection Kit (Life Technologies, USA). Next, the slides were incubated with Opal TSA fluorochromes diluted in an amplification buffer (Akoya biosciences, USA). The primary and secondary antibody complex was stripped by microwave treatment with 0.05% ProClin300/Tris&ndash;EDTA buffer at pH 9.0. Finally, DAPI working solution (Akoya biosciences, USA) was applied and the slides were mounted with Prolong Diamond Anti-fade mounting medium (#P36965; Life Technologies).</p> <ul> <li>Image processing</li> </ul> <p>Stained slides were scanned using the Vectra Polaris Automated Quantitative Pathology Imaging System (Akoya biosciences, USA). From each slide, representative tumor regions and regions at the junction of tumor and surrounding cerebral tissue were selected and&nbsp;multispectral imaging&nbsp;(MSI)&nbsp;images&nbsp;were&nbsp;acquired at 40x resolution. After image capture, the images were spectrally unmixed and analyzed, using supervised machine learning algorithms within Inform 4.2.2. (Akoya biosciences). Cells were assigned into ten different phenotype categories: &ldquo;PAX5+PD-L1-&rdquo;, &ldquo;PAX5+PD-L1+&rdquo;, &ldquo;CD163+PD-L1-&rdquo;, &ldquo;CD163+PD-L1+&rdquo;, &ldquo;CD3+CD8-PD-1-&rdquo;, &ldquo;CD3+CD8+PD-1-&rdquo;, &ldquo;CD3+CD8-PD-1+&rdquo;, &ldquo;CD3+CD8+PD-1+&rdquo;, &ldquo;other PD-L1+&rdquo; or &ldquo;other&rdquo;, based on the size of the cells and positivity of markers in the panel.&nbsp;</p> <p>&nbsp;</p>

opencc-by-4.0Dec 2022View details →
ClinicalTrials.gov36/100

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

ClinicalTrials.gov study NCT00335140. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

ClinicalTrials.gov study NCT02301364. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of T

ClinicalTrials.gov study NCT00945724. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

ClinicalTrials.gov study NCT00068250. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

ClinicalTrials.gov study NCT00594815. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

ClinicalTrials.gov study NCT01011920. IPD Sharing: Not stated. Countries: 4. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

ClinicalTrials.gov study NCT00000801. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

ClinicalTrials.gov study NCT03703167. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma

ClinicalTrials.gov study NCT05600660. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

ClinicalTrials.gov study NCT07104032. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

ClinicalTrials.gov study NCT00002676. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma

ClinicalTrials.gov study NCT01956695. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma

ClinicalTrials.gov study NCT04934579. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central

ClinicalTrials.gov study NCT02315326. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

ClinicalTrials.gov study NCT00863460. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.

ClinicalTrials.gov study NCT06263361. IPD Sharing: NO. Countries: 1. Publications: 9.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma

ClinicalTrials.gov study NCT00942747. IPD Sharing: Not stated. Countries: 1. Publications: 6.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

ClinicalTrials.gov study NCT04831658. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record